Key terms
About CING
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in 2013 and is headquartered in Kansas City, KS.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CING news
Apr 04
11:05am ET
Cingulate Inc (CING) Receives a Hold from Maxim Group
Apr 01
8:07am ET
Cingulate reports Q4 EPS net loss $6.9M
Feb 13
7:02am ET
Cingulate Inc Bolsters Board, Targets Nasdaq Compliance
Feb 02
9:16am ET
Cingulate prices 3.75M shares at $2.00 in public offering
Jan 12
5:05pm ET
Cingulate files to sell common stock and warrants, no amount given
Jan 05
7:55am ET
Cingulate Inc: A Strong Buy on Promising ADHD and Anxiety Treatments and Favorable FDA Interactions
Jan 05
7:41am ET
Cingulate price target raised to $8 from $3.50 at H.C. Wainwright
CING Financials
Key terms
Ad Feedback
CING Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CING Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
